Logo

Kinaxo Using Proteomics Technology for Bristol-Myers Squibb Rx Discovery

Oct 11, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Kinaxo Biotechnologies will be using its technologies to support Bristol-Myers Squibb's drug discovery programs.

Under a deal announced today, Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work. The research, Kinaxo said, will allow Bristol-Myers Squibb to make more informed decisions at different stages of the drug discovery process, such as selecting the best compounds for clinical development.

Terms of the deal were not disclosed.

In a statement, Jutta Fritz, head of business development for Kinaxo said the agreement is a "major milestone" as the company expands its business into the US.

Filed under

Proteomics & Protein Research
Diagnostics
ABRF
proteomics
BMS
Evotec
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.